A股、港股生物医药板块再度大涨，创新药ETF天弘(517380)涨超4%，机构：建议加配医药板块

Group 1 - The A-share and Hong Kong stock markets' biopharmaceutical sector experienced significant gains, with the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index rising by 3.74% [1] - Key stocks in the index included King’s Ray Biotechnology, which surged over 16%, and Innovent Biologics, which increased by over 14% [1] - The Tianhong Innovative Drug ETF (517380) also saw a rise of over 4%, with a trading volume of 16.337 million yuan and a real-time premium rate of 0.01% [1] Group 2 - The Guozheng Biopharmaceutical Index (399441.SZ) rose by 2.05%, with notable increases in stocks such as Diligent Pharma-U and Kangtai Biological, both rising over 6% [2] - The biopharmaceutical ETF (159859) tracking this index increased by 1.91%, with a trading volume of 89.9998 million yuan, making it the largest product in its category [2] - The recent performance of the pharmaceutical sector was attributed to a partnership between BioNTech and BMS, which involved a $1.5 billion upfront payment, boosting investment enthusiasm in innovative drugs [2]